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Abstract
Background: Prenatal diagnostics ultrasound was established in Russia in 2000 as a routine method of screening
for birth defects. The aims of the current study were twofold: to assess changes in birth defects prevalence at birth
and perinatal mortality after ultrasound screening was implemented and to estimate prenatal detection rates for
congenital malformations in the city of Monchegorsk (Murmansk County, North-West Russia).
Methods: The Murmansk County Birth Registry and the Kola Birth Registry were the primary sources of information,
and include 30 448 pregnancy outcomes in Monchegorsk for the period 1973–2011. Data from these registries
were supplemented with information derived from hospital records about pregnancy terminations for 2000–2007.
Results: The total number of newborns with any kind of birth defects in Monchegorsk during 1973–2011 was 1099,
of whom 816 were born in the 1973–2000 period. The prevalence of defects at birth increased from 34.2/1000
(95 % CI = 31.9-36.5) to 42.8/1000 newborns (95 % CI = 38.0-47.7) after prenatal ultrasound screening was formally
implemented. We observed significant decreases (p < 0.05) in the birth prevalence of congenital malformations of
the circulatory system, the musculoskeletal system (including deformations), and other (excluding multiple); those
of the urinary system increased from 0.9/1000 to 17.1/1000 (p < 0.0001). The perinatal mortality among newborns
with any kind of malformation decreased from 106.6 per 1000 newborns with birth defects (95 % CI = 84.3-129.1)
to 21.2 (95 % CI = 4.3-38.1). Mothers who had undergone at least one ultrasound examination during pregnancy
(n = 9883) had a decreased risk of having a newborn die during the perinatal period [adjusted OR = 0.49 (95 %
CI = 0.27-0.89)]. The overall prenatal detection rate was 34.9 % with the highest for malformations of the nervous
system.
Conclusion: Improved detection of severe malformations with subsequent pregnancy termination was likely the
main contributor to the observed decrease in perinatal mortality in Murmansk County, Russia.
Keywords: Prenatal diagnostics, Screening, Ultrasound diagnostic, Birth defects, Murmansk County Birth Registry,
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Background
Prenatal diagnosis is the identification of birth defects
prior to delivery and constitutes a routine practice in
most of European countries [1]. Prenatal screening (PS)
is now recognized as the key issue in the early detection
and correction of birth defects (BD) [2]. The first assess-
ments of impacts of PS on perinatal mortality were
presented in the early 1990s. They were based on random-
ized control studies and considered controversial. While a
study in Helsinki showed a reduction in perinatal mortal-
ity [3], this outcome was not supported by the findings of
the multicenter Radius trial in the USA [4].
The effectiveness of PS can be estimated by the pre-
natal detection rate, which represents the proportion of
BD recognized before delivery. It depends on the type of
defect, quality of equipment and experience of the oper-
ator. According to the European Surveillance of Con-
genital Anomalies (EUROCAT) data, 64 % of BD could
be diagnosed before birth although it varies widely, from
94 % for anencephaly to 87 % for omphalocele, and as
low as 27 % for the transposition of great vessels [5]. For
chromosomal anomalies, the reported average ultra-
sound detection rates ranged widely: 5.7 % (Klinefelter
syndrome) to 78.6 % (triploidy); for Down syndrome it
was 26.4 % [6], and 19.9 % for cardiovascular malforma-
tions (11 % for isolated cases and 40 % for multiple mal-
formations) [7].
The PS of malformations has an influence on the still-
birth rate, as they lead to terminations of pregnancies
when severe defects are diagnosed. Surgical correction
of defects during the first days of life can also reduce
neonatal mortality [8].
In Russia, prenatal ultrasound examination was estab-
lished in the early 1990s, and became part of a screening
program offered to all pregnant women in compliance
with a national law promulgated in 2000. It is free of
charge and is offered by obstetricians to every pregnant
woman. Refusal must be put in writing. The Russian
Ministry of Health stipulates a two-stage approach to PS
[9]. Initially, PS applies to all pregnant women and is
carried out in obstetrics out-patient departments. It in-
cludes ultrasonography between weeks 10–14, 20–24
and 30–32 of gestation. During the second trimester,
biochemical tests of blood alpha-fetoprotein and chori-
onic gonadotropin are administered. The second stage
involves regional medical-genetic consultations and
measures directed at establishing the exact diagnosis and
prognosis of the fetus. Different approaches could be
adopted at this stage involving non-invasive (ultrasound,
cardiotocography, Doppler mapping) and/or invasive
(amniocentesis, chordocentesis, placentocentesis, and
chorion aspiration) procedures as required. If a diagnosis
of BD is confirmed, an Advisory board (Perinatal Consi-
lium) suggests a future management plan, or advises
pregnancy termination in case of incurable BD. Never-
theless, the final decision about how to proceed is made
by the woman. According to Russian law [10], termin-
ation of pregnancy in case of BD is possible at any ges-
tational age, but a woman’s decision to do so late in the
pregnancy needs approval by the Perinatal Consilium.
In case of chromosomal anomalies, termination is pos-
sible until and including week 22, later decision needs
approval.
Ten years after the establishment of PS in Russia, it is
pertinent to assess its efficiency in the detection of BD
and impact on pregnancy continuations. However, the
available information is limited. In 2001–2003, researchers
from the Komi republic (Northwestern District) estimated
a prenatal detection rate based on more than 29 thou-
sands pregnancies, and reported that it was the highest
(74.5 %) for neural tube defects and lowest (4.7 %) for
cardiovascular malformations; for Down syndrome it
was 33.3 % [11]. Another study in Samara (Volga Dis-
trict) noted that the occurrence of abortion in case of
lethal BD increased from 8.75 % in 2000–2001 to
24.20 % in 2004–2007 [12].
A countywide population-based birth registry estab-
lished in 2005 for Murmansk County provides a unique
opportunity to study BD epidemiology at the population
level [13]. Since living in an industrialized region of the
Northwest Russian Arctic might influence reproductive
health and pregnancy outcomes, we selected the city of
Monchegorsk located in the Kola Peninsula for analysis.
We previously reported a steady increase during 2003–
2011 in the birth prevalence of BD for this community,
with significant growth in the birth prevalence of de-
fects of the nervous system and urinary malformations.
It was suspected that one of the underlying reasons for
the increase was the establishment of PS [14]. The ob-
jectives of the present study are: (i) determine the influ-
ence of PS on the prevalence at birth of BD and
perinatal mortality, and (ii) estimate the prenatal detec-
tion rates for all groups of BD.
Methods
Study design and sources of information
Our study population includes all newborns delivered in
Monchegorsk during the period 1973–2011 and regis-
tered either in the Kola Birth Registry (KBR) or in the
Murmansk County Birth Registry (MCBR).
The KBR was established in 1998 by a retrospective re-
trieval from hospital delivery department records of in-
formation about all births from week 28 of gestation on
that occurred in Monchegorsk as of March 1973. Regis-
tration continued prospectively until the end of 2005.
Details of its construction, description, suitability for epi-
demiological studies and selected applications are avail-
able [13, 15, 16]. The MCBR was established in 2005,
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and prospectively registers pregnancy outcomes from
22 weeks of gestation on as January 1, 2006 [17]. The
technicalities of merging the two registries were pre-
sented previously, as well as the Monchegorsk perinatal
statistics [14].
Routine prenatal ultrasound examinations began in
Monchegorsk in 1994 [16], although some earlier cases
were recorded in the KBR. The latter were associated
with severe pregnancy complications that were usually
performed after 22 weeks of gestation, and consequently
cannot be considered as constituting prenatal diagnos-
tics. Until 2000, ultrasound screening was performed
during the 19th week of pregnancy in cases with medical
indications [16]. According to the KBR data, 4718
women (70.6 %) had ultrasound examinations during
pregnancy in the period 1994–2000, but this figure var-
ied from 47.5 % in 1994 to 94.8 % in 2000. From 2001
on, the local hospital abided by the mentioned National
law and conducted three examinations during pregnancy
[9]. The information about ultrasound examination was
recorded in the registry, and included gestational age at
examination as well as the pathological findings. In the
MCBR, gestational age at the first examination is regis-
tered, and the pathological findings from all examina-
tions are indicated. However, the MCBR does not
contain information about biochemical screening, as it
only became part of clinical practice in the early 2000s;
it had relatively low coverage during the implementation
period.
In order to obtain a precise estimate of the prenatal de-
tection rate, the data from the registries were supple-
mented by information from the Monchegorsk Municipal
Hospital for the years 2000–2007 concerning terminated
pregnancies linked to BD at gestational ages less than
28 weeks. It included the results of PS (including diagno-
sis), gestational age at diagnosis and termination. Such
data were not available for 2008–2011 and, consequently,
prenatal detection rates were limited to the 2000–2007
period.
Data analysis
To compare changes before and after PS implementa-
tion, the prevalence of BD at birth were calculated for
the periods 1973–2000 and 2001–2011 using data from
the two registries. We also assessed the birth prevalences
of BD for which reporting is mandatory in Russia. They
include the 22 most severe forms of BD as described in
detail in our previous publication [14]. At this stage, all
newborns were included for whom there was informa-
tion about BD and their status at birth and during the
first week of life (n = 30 448).
We stratified perinatal mortality for all newborns (with
and without BD) into three time-periods: 1973–2000,
1990–2000, and 2001–2011. It was calculated as the
sum of stillbirths and deaths during the first week of life
per total births. Differences in birth prevalences and
mortality rates within these time-periods were analyzed
by the chi-squared test. We considered the time span
between 1990 and 2000 to have been influenced by slow
technical progress and changing registration methods.
The effect of PS on perinatal mortality was estimated
by logistic regression. Altogether, 10 317 newborns out
of 10 502 born in the years for whom ultrasound tech-
nology was available (1994 or later) were included in the
analysis. Of these newborns, 185 (1.8 %) had missing in-
formation; gestational age was missing for 103 (1.0 %),
76 (0.7 %) had no information about PS, and both fields
were missing in six (0.1 %). Perinatal death was included
as a dependent variable, while ultrasound screening was
a binary variable with positive values if at least one ultra-
sound examination had occurred. Gestational age, year
of birth, maternal age and previous history of perinatal
deaths were included in the model as independent vari-
ables (all were tested for multi-collinearity).
We estimated prenatal detection rates for all groups of
BD according to The International Statistical Classifica-
tion of Diseases and Related Health Problems 10th revi-
sion (ICD-10) for 2000–2007, and compared the PS data
with perinatal diagnoses. The information available from
the statistical department of the local hospital about
pregnancy terminations due to fetal anomaly (TOPFA)
were included in the analysis at this stage. Rates were
calculated as the total number of newborns with BD di-
agnosed during ultrasound screening divided by the total
number of newborns with BD. The newborns were in-
cluded in the numerator only when the diagnosis at
screening, at birth, and during the first week of life
matched. The effect of TOPFA on perinatal mortality
and on the stillborn rate were estimated by computing
rates that combined registry data with the pertinent hos-
pital information.
All statistical analyses were performed using SPSS
21.0.
Ethical considerations
No personal maternal information such as first name,
surname or address is recorded in the registries, so writ-
ten consent could not be obtained from the mothers.
The KBR was established retrospectively [13, 15, 16],
with approval from the Murmansk County Health Au-
thority (MCHA). In case of the MCBR, the MCHA
passed legislation making birth registration and collec-
tion of pertinent medical data from hospital records
mandatory. Nevertheless, each woman was informed at
the first antenatal visit about the inclusion of such infor-
mation in the registry database [17]. The creation of
both registries and its protocols were approved by the
Murmansk County Committee for Research Ethics
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(Murmansk, Russia) and the Regional Committee for
Medical and Health Research Ethics (Tromsø, Norway).
The latter and the Committee for Research Ethics at the
Northern State Medical University (Arkhangelsk, Russia)
approved the current study.
Results
Prevalence of birth defects at birth before and after the
establishment of PS
There were 1099 newborns with any kind of BD during
1973–2011 in Monchegorsk; 816 of them were born in
the pre-screening period (1973–2000) and 283 were
born after its formal implementation (Table 1). The total
prevalence at birth increased 24 % after PS was formally
implemented (42.8 per 1000 newborns versus 34.2 per
1000 newborns). By contrast, the corresponding preva-
lence of the most severe defects (reporting of which is
mandatory) did not change (Table 1).
Significant changes (p ≤ 0.03) in prevalence at birth
were observed for congenital malformations of the circu-
latory system, the musculoskeletal system (including de-
formations), the urinary system and the group of other
congenital malformations. A substantial increase was
evident only for BD of the urinary system (Table 2).
Decreasing of perinatal mortality
During the 1973–2000 study period, there were 572
cases of perinatal deaths, of which 297 were stillborn. Of
these, 506 perinatal deaths (Table 2) and 244 fetal deaths
were registered during 1973–2000. Consequently, the
perinatal mortality rate decreased from 21.2 per 1000
newborns (95 % CI: 19.4-23.1) in 1973–2000 to 10.0 (95
% CI: 7.6-12.3) in 2001–2011. In the 1990–2000 transi-
tional period, the perinatal mortality rate was 18.4 (95 %
CI: 15.2-21.6) per 1000 newborns. Compared to the early
and transitional periods, the perinatal mortality for all
newborns and newborns without BD decreased two-fold
during 2001–2011. Furthermore and relative to the
screening period, the perinatal mortality among new-
borns with any kind of malformation was 5 times higher
for the pre-screening period and 2.5-fold for the transi-
tion time frame (see Table 3).
The logistic regression analysis indicated that mothers
who had undergone at least one ultrasound examination
during pregnancy (n = 9 883), had a lower risk of having
a newborn die during the perinatal period [adjusted
OR = 0.49 (95 % CI: 0.27-0.89)].
Prenatal detection rates and terminations of pregnancies
due to fetal anomalies
Of 4 596 newborns in the 2000–2007 cohort whose
mothers had undergone at least one ultrasound proced-
ure during pregnancy, 182 had a registered BD; of these,
56 were recognized before birth. In addition, 25 preg-
nancies had been terminated before gestational age of
28 weeks, and had not been reported in the registries.
Consequently, the total number of prenatally diagnosed
BD were 81 of 232, with an overall prenatal detection
rate of 34.9 % (for the complete list stratified by birth
defect group see Table 4).
Prenatal diagnoses of the BD pertaining to the 25
pregnancy terminations involved the nervous system
(40 %; n = 10), the circulatory system (20 %; n = 5),
multiple malformations (20 %; n = 5), congenital malfor-
mations of the kidney (8 %; n = 2), diaphragm hernia
(8 %; n = 2), other malformations (4 %; n =1).
After inclusion of TOPFA in the mortality analysis,
the stillborn rate in 2000–2007 increased to 13.8/1000
(95 % CI = 10.9-13.6) from that based on the registry
data [8.5/1000 (95 % CI 5.8-11.1)].The perinatal mortal-
ity was 17.7/1000 (95 % I = 14.7-22.0) versus 12.4/1000
(95 % CI = 9.2-15.6). Consequently, the estimated re-
duction in the stillborn rate linked to the abortion of
fetuses with severe BD was 38 %, and 30 % for perinatal
mortality.
Discussion
Perinatal mortality
Our study showed clearly that the implementation of PS
had an impact on perinatal mortality and BD prevalence.
The five-fold decrease observed in perinatal mortality
among newborns after the implementation of PS
exceeded that reported for the mentioned Helsinki trial
[3]. The latter study covered a 19-month period, while
Table 1 The total prevalence of malformations at birth before and after prenatal screening was formally instituted
Number or Prevalence 1973-2000 2001-2011 p-value1
Number of newborns included in the analysis 23 822 6626
Number of newborns with BD 816 283
Prevalence of BD at birth (per 1000 newborns)2 34.2 (31.9-36.5)2 42.8 (38.0-47.7) 0.001
Number of newborns with forms of BD requiring
mandatory reporting
175 48
Prevalence at birth of BD forms requiring mandatory
reporting (per 1000 newborns)2
7.3 (6.3-8.4) 7.3 (5.2-9.4) 0.500
1 Chi-squared test
2 95 % confidence intervals are given in parentheses
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the current work embraced 38-years during which med-
ical practices, technics and management protocols chan-
ged drastically. By comparison, the perinatal mortality
among newborn without birth defects only halved. The
most probable reason is the termination of pregnancies
due to incompatible-with-life defects, of which there
were 25 in 2000–2007.
The prevalence of TOPFA in 2000–2007 was 5.4 per
1000 births. In Europe, such indicator varies from zero
in Ireland, Malta and Poland (where termination of
pregnancies is illegal) to 10/1000 births in France [18].
In Russia, the legislation concerning abortions for med-
ical reasons may be considered to be rather liberal as
mentioned above [10]. There is no list of BD that are
considered as lethal or incompatible with life [10]. All
cases of prenatal diagnosis of BD are scrutinized indi-
vidually. Nevertheless, abortions based on medical indi-
cations appear to constitute a small proportion (less
than 3 % in 2010). Whereas the reported rate of all preg-
nancy terminations decreased 49.6 % over the past
20 years in Russia [19], those in Murmansk County de-
creased from 166 per 100 births in 2000 to 58 per 100
births in 2010 [20]. The proportion of abortions for
medical reasons increased from 2.2 % in 2000 to 4.2 %
in 2006, with a subsequent decrease to 2.4 % in 2008.
The decline in overall terminations rate could be due to
the improving socio-economic situation, the lowering in
social indicators for abortions in both 2003 and 2011
[21, 22] from 13 to one (pregnancy resulting from sexual
assault), and a cutback in the number of medical criteria
in 2007 [10]. It is important to note that these changes
do not apply to BD.
At first glance, one might suggest that the establish-
ment of screening has not influenced pregnancy con-
tinuation. It could be argued that due to the multiplicity
of medical reasons for termination the dynamics of
Table 2 Malformation prevalence at birth, stratified by anomaly groups before and after the establishment of prenatal screening,
per 1000 newborns
Group of birth defect (ICD-10 codes) 1973-2000 2001-2011 p-value1
Number (N) of newborns: 23 822 Number (N) of newborns: 6626
N of BD Prevalence2 N of BD Prevalence2
Congenital malformations of the nervous system (Q00-Q07) 40 1.7 (1.2-2.2) 14 2.1 (1.0-3.2) 0.450
Congenital malformations of eye, ear, face and neck (Q10-Q18) 11 0.5 (0.2-0.7) 6 0.9 (0.2-1.6) 0.174
Congenital malformations of the circulatory system (Q20-Q28) 58 2.4 (1.8-3.1) 7 1.1 (0.3-1.8) 0.032
Congenital malformations of the respiratory system(Q30-Q34) 26 1.1 (0.7-1.5) 3 0.5 (0–1.0) 0.138
Cleft lip and cleft palate (Q35-Q37) 31 1.3 (0.8-1.8) 7 1.1 (0.3-1.8) 0.624
Congenital malformations of the digestive system (Q38-Q45) 29 1.2 (0.8-1.7) 7 1.1 (0.3-1.8) 0.743
Congenital malformations of genital organs (Q50-Q56) 86 3.6 (2.8-4.4) 26 3.9 (2.4-5.4) 0.696
Congenital malformations of the urinary system (Q60-Q64) 21 0.9 (0.5-1.3) 113 17.1 (14.0-20.2) <0.0001
Congenital malformations and deformations of the
musculoskeletal system (Q65-Q79)
323 13.5 (12.1-15.0) 63 9.5 (7.2-11.9) 0.010
Other congenital malformations, excluding multiple
(Q80-Q89, excluding Q 89.7)
98 4.1 (3.3-4.9) 12 1.8 (0.8-2.8) 0.007
Chromosomal abnormalities (Q90-Q99) 17 0.7 (0.4-1.1) 5 0.8 (0.1-1.4) 0.807
Multiple congenital malformation, not classified 76 3.2 (2.5-3.9) 20 3.0 (1.7-4.4) 0.937
1 p-value for chi-squared test
2 95 % confidence intervals are presented in parentheses
Table 3 Actual number (N) and prevalence of perinatal deaths (per 1000 newborns) before and after the establishment of prenatal
screening
Group of newborns 1973-2000 1990-2000 2001-2011 p-value1
N Prevalence2 N Prevalence2 N Prevalence2
Newborns with BD (N = 1099) 87 106.6 (84.3-129.1) 18 52.9 (32.5-85.9) 6 21.2 (4.3-38.1) <0.00013
0.01604
Newborns without BD (N = 29 349) 419 18.2 (16.5-19.9) 105 16.5 (13.3-19.6) 60 9.5 (7.1-11.8) <0.00013
<0.00014
1 p-value is for chi-squared test
2 95 % confidence intervals are presented in parentheses
3 For the 1973–2000 and 2001–2011 groups
4 For the 1990–2000 and 2001–2011 groups
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abortion incidence could not truly represent the influ-
ence of PS. However, our results contradict this. Adjust-
ment by year in the logistic regression analysis excluded
a potential influence of medical progress over time, and
this suggested that the effect of decreasing the number
of perinatal deaths was related to the early detection of
pathological conditions and medical intervention. More
accurate determination of gestational age was likely an
issue as well.
Birth prevalence of birth defects
The observed increase in the birth prevalence of BD
during 2001–2011 (Table 2) may largely attributed to an
increase in the prevalence of the urinary system malfor-
mations. It is correlated with a high prenatal detection
rate for this malformation group and may indicate over-
diagnosis. This appears to be so for Q62.0 (congenital
hydronephrosis) and Q63.0 (another malformations of
kidney, unspecified), as they represent more than a half
of all urinary malformations in Monchegorsk. Similarly,
and based on prenatal ultrasound examination, Luck
[23] also reports a high prevalence of hydronephrosis
(95 cases from 140 cases of all BD). Over-diagnosis of
this malformation could be due to difficulties in differen-
tiating between the physiological size of renal pelvis and
renal pathological dilatation, although national guide-
lines at the time the PS was conducted were absent. The
prevalence of cardiovascular BD has significantly chan-
ged after PS implementation. This group consists of ra-
ther severe defects, which often are incompatible with
life and thus their prenatal diagnosis can lead to preg-
nancy termination. Consequently, the observed decrease
in their prevalence might reflect improved diagnoses
before birth with subsequent terminations (20 % of
total). We did not find an increase in the prevalence of
ventricle and atrial septal defects as reported by other
authors [24, 25]. Perhaps our short follow-up period,
which ended with the discharge from the maternity
ward, may have precluded it.
The prevalence of the most severe BD that require
mandatory registration was stable over the two main
study periods. It constitutes a heterogeneous group of
defects, some of which could be corrected by surgery,
while others are incompatible with life. Perhaps an in-
crease in the prevalence of the former may have in-
creased pregnancy termination since after the
establishment of PS no cases were registered at birth of
anencephaly, diaphragmatic hernia and omphalocele;
and only one case each of cleft palate and gastrosсhisis.
The prevalence of Down syndrome decreased, but not
statistically so (comparison was limited by relatively
small n, namely 6606 newborns after 2000).
A decrease in musculoskeletal malformation’s preva-
lence (see Table 2) did not correlate with their detection
rate, which is one of the lowest (see Table 4). Neither does
the observed absence of pregnancy terminations due to
these malformations seem likely. Presumably, a true
prevalence decrease occurred. Possibly the mothers were
transferred for delivery to central clinics (Murmansk,
Saint-Petersburg, Moscow) and, accordingly, information
about such newborns were not included in the registries.
Prenatal detection rates and perinatal prevalence
The observed antenatal detection rate of malformations
was low – less than a half of those diagnosed after birth.
It was lower than that disclosed in the EUROSCAN
Table 4 Prenatal detection rates, stratified by birth defects groups in Monchegorsk in 2000–2007 (including terminations of
pregnancies due to fetal anomaly)
Group of birth defect Number of BD Number of BD diagnosed
before birth
Prenatal detection rate, %
Congenital malformations of the nervous system 25 17 68.0
Congenital malformations of eye, ear, face and neck 3 0 0
Congenital malformations of the circulatory system 12 7 58.3
Congenital malformations of the respiratory system 3 0 0
Cleft lip and cleft palate 3 2 66.7
Other congenital malformations of the digestive system 4 0 0
Congenital malformations of genital organs 21 0 0
Congenital malformations of the urinary system 76 32 42.1
Congenital malformations and deformations of the
musculoskeletal system
47 5 10.6
Other congenital malformations, excluding multiple 11 9 81.8
Chromosomal abnormalities 4 1 25.0
Multiple congenital malformation, not classified 23 8 34.8
All birth defects 232 81 34.9
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study [1, 5]. However, the EUROSCAN investigation con-
sidered detection rates for only 11 severe defects, while
our study considered all BD. Taking into account all mal-
formations, the prenatal detection rate in Europe was
31.8 % in 2008–2012 [26] and thus was comparable to
ours. Nevertheless, the prenatal detection rate in our study
could be an overestimate for some groups of minor de-
fects that subsequently could not be recognized during
the first week of life. Thus, our estimation is most valid
for easily diagnosed defects, such as of the nervous sys-
tem, orofacial or muscular-skeletal anomalies; for these,
the EUROCAT detection rates were higher [26].
Our data is similar to the Russian studies mentioned
earlier [11], with urinary malformations and cardiovas-
cular defects the exceptions. The observed antenatal
prevalence of 1.2 % is comparable to that reported in a
systematic review covering the late 1990s (based primar-
ily on USA and European studies) [27].
The Russian system of perinatal diagnostics has pri-
marily focused on municipal out-patients departments
(“women’s consultations”), staffed with specialists in
ultrasound diagnostics. The mean number of examina-
tions per woman during pregnancy was high, although
of rather poor quality, as half of the malformations were
not diagnosed before birth [28]. Some Russian re-
searchers have shown that the municipal administration
of PS has been inefficient, and suggested that regional
centers with more experienced staff be established [29].
A primary feature of the PS program in Monchegorsk
is the poor detection of chromosomal defects. For ex-
ample, no diagnosis of Down syndrome was made before
birth. The likely reason is that Monchegorsk is a rela-
tively small city (about 45 000 inhabitants compared to
around 300 000 in Murmansk), and such municipal hos-
pitals have been recognized to have problems with both
the quality of the medical equipment and of medical
staff training, especially during the first years of PS.
Chromosomal defects are difficult recognize and diag-
nose. They were more frequently addressed in regional
clinics, which are staffed with genetic specialists and
consultants for the second stage of PS, as described
above.
Strengths and limitations
Our study is the first in Northern Russia to analyze the
effectiveness of PS at the population level that is based
on validated sources of information, including TOPFA
data. Furthermore, the two birth registries used provided
full coverage of all pregnancy’s outcomes, although our
study was limited to information about BD diagnosed
during the first week of life. The latter could have led to
a possible underestimation of the prevalence of small
birth defects, although it did not influence the prenatal
mortality. We did not have data on TOPFA for the
whole study period, and consequently could not include
them in the prevalence analyses. Thus, we aimed to esti-
mate prevalence at birth and, we suppose, that inclusion
of TOPFA would have increased the estimated preva-
lence somewhat. In this instance, prevalence of severe
BD would also have increased. Some pregnant women
suspected to give birth to newborns with serious BD did
so at major hospitals in Murmansk, Moscow or Saint
Petersburg and their neonates were not included in our
analysis. Inclusion of such newborns could increase the
prenatal detection rates, but the proportion of such
cases was not high. For example, according to the data
provided by the Monchegorsk Hospital six newborns
(6.8 %) with prenatally diagnosed BD (2.5 % of all new-
borns with BD) were born in Murmansk or Moscow.
Due to differences in coding between registries and the
large proportion (up to 5 %) of missing information, our
regression model did not include all possible con-
founders such as comorbidities of mothers and compli-
cations of pregnancy, previous history of stillborn and
maternal socio-economic status.
Conclusion
The birth prevalence of BD doubled after the introduc-
tion of routine PS, but less than half of the defects were
diagnosed before birth. Improved detection of severe
malformations with subsequent termination is likely to
have been the main contributor to the observed decrease
in perinatal mortality during 2001–2011 in Murmansk
County, Russia.
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